<DOC>
	<DOC>NCT02561806</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.</brief_summary>
	<brief_title>A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Chronic plaque psoriasis for at least 6 months before baseline Failure, contraindication, or intolerability to at least 1 systemic therapy (including cyclosporine, methotrexate, or phototherapy) PASI score at least 10 at screening and at baseline Participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 15 weeks after stopping treatment Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis History of druginduced psoriasis Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks before baseline and during the study Have received systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks of baseline, or have had topical psoriasis treatment within the 2 weeks of baseline Concurrent or recent use of any biologic agent within the following washout periods: etanercept &lt;28 days; infliximab, adalimumab, or alefacept &lt;60 days; golimumab &lt;90 days; rituximab &lt;12 months; or any other biologic agent &lt;5 halflives prior to baseline Have prior use of ustekinumab, or have any condition or contraindication to ustekinumab that would preclude the participant from participating in this protocol Have previously completed or withdrawn from this study, participated in any other study with ixekizumab, have participated in any study investigating other interleukin (IL)17 or IL12/23 antagonists, or have received treatment with other IL17 or IL12/23 antagonists Have had a live vaccination within 12 weeks of baseline, or intend to have a live vaccination during the course of the study or within 15 weeks of completing treatment in this study Have had a vaccination with Bacillus CalmetteGu√©rin (BCG) within 12 months of baseline or intend to have vaccination with BCG during the course of the study or within 12 months of completing treatment in this study Have a known allergy or hypersensitivity to latex Have had any major surgery within 8 weeks of baseline or will require such during the study Have active or history of malignant disease within 5 years prior to baseline Significant uncontrolled disorder Ongoing infection or serious infection within 12 weeks of baseline; serious bone or joint infection within 24 weeks of baseline Are women who are lactating or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>